{"paper_id":"099bb7e2-125e-42d3-8356-e2537c96c21d","body_text":"References\nLemayA. (1987). Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.Fertil. Steril.,48, 10–12\nLemayA. (1989). Clinical appreciation of LHRH analogue formulations.Horm. Res.,32, 93–102\nNilliusS.J., BergquistC. and WideL. (1978). Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue—a new approach to birth control?Contraception,17, 537–545\nBergquistC., NilliusS.J. and WideL. (1979). Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.Contraception,17, 497–506\nBergquistC., NilliusS.J. and WideL. (1979). Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.Lancet,1, 215–216\nSchmidt-GollwitzerM., HardtW., Schmidt-GollwitzerK., von derOheM. and Nevinny-StickelJ. (1981). Influence of the LH-RH Analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?Contraception,23, 187–195\nHardtW., Schmidt-GollwitzerM., von derOheM. and Nevinny-StickelJ. (1981). Der Einfluß der Dauer-medikation des LH-RH Analogons Buserelin auf die Zyklusregulation.Geburtsh. Frauenheilk.,41, 791–796\nBergquistC., NilliusS.J., WideL. and LindgrenA. (1981). Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.Fertil. Steril.,36, 339–342\nBerquistC., NilliusS.J. and WideL. (1982). Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.Fertil. Steril.,38, 190–193\nGudmundssonJ.A., NilliusS.J. and BerquistC. (1984). Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.Contraception,30, 107–114\nNilliusS.J. (1985). Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.J. Steroid. Biochem.,23, 849–854\nBrennerP.F., ShoupeD. and MishellD.R.Jr (1985). Ovulation inhibition with nafarelin acetate nasal administration for six months.Contraception,32, 531–551\nGudmundssonJ.A., NilliusS.J. and BerquistC. (1986). Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.Fertil. Steril.,45, 617–623\nMonroeS.E., BlumenfeldZ., AndreykoJ.L., SchriockE., HenzlM.R. and JaffeR.B. (1986). Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (Nafarelin).J. Clin. Endocrinol. Metab.,63, 1334–1341\nLundkvistO. and BerquistC. (1985). Morphological studies of human endometrium during continous LH-RH agonist treatment.Int. J. Fertil.,30, 65–70\nGudmundssonJ.A., LjunghallS., BerquistC., WideL. and NilliusS.J. (1987). Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition.J. Clin. Endocrinol. Metab.,65, 159–163\nFraserH.M., DewartP.J., SmithS.K., CowenG.M., SandowJ. and McNeillyA.S. (1989). Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.J. Clin. Endocrinol. Metab.,65, 996–1002\nDewartP.J., McNeillyA.S., SmithS.K., SandowJ., HillierS.G. and FraserH.M. (1987). LHRH agonist buserelin as a post-partum contraceptive: lack of biological activity of buserelin in breast milk.Acta Endocrinol. (Copenh.),114, 185–192\nHardtW., Schmidt-GollwitzerK., Nevinny-StickelJ. and Schmidt-GollwitzerM. (1982). Fortschritte in der Kontrazeptiven anwendung des LH-RH-agonisten Buserelin: diskontinuierliche Medikation mit gestagenin-duzierter Abbruchblutung.Geburtsh. Frauenheilk.,42, 874–877\nLemayA., FaureN., LabrieF. and FazekasA.T.A. (1985). Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.Fertil. Steril.,43, 868–877\nLemayA. and FaureN. (1986). Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.J. Clin. Endocrinol. Metab.,63, 1379–1385\nLemayA., FaureN. and BastideA. (1987). Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.Fertil. Steril.,47, 60–66\nLemayA., JeanC. and FaureN. (1987). Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.Fertil. Steril.,48, 775–782\nGeisthovelF., JenneD., WieackerP. and BreckwoldtM. (1987). Cyclic administration of an LHRH analogue and of progesterone in risk patients to oral contraceptives.Contraception,36, 459–469\nGeisthovel, F., Wieacker, P., Greif, M. and Breckwoldt, M. (1989). Buserelin and progesterone (P) in risk patients to oral contraceptives (OC). The XIII World Congress on Fertility and Sterility, Marrakesh, October 1989, p. 563 (Abstr.)\nBirkhäuser, M.H., Witthaus, E., Werner, I. and Huber, P. (1989). Contraception by a cyclic buserelin/gestagen-combination: result of 410 contraceptive cycles. Presented at the International Symposium entitled: ‘The present place of LHRH analogues in gynaecology’, Brussels Congress Centre, Belgium, June 9–10, 1989\nSchumacherT., ZwirnerM., UnterbergH., PohlC., KellerE. and SchindlerA.E. (1984). Effects of the LHRH-analogue buserelin given discontinuously as a contraceptive on ovarian cycle and lipometabolism.Neuroendocrinol. Lett.,6, 267–272\nLemayA. and Dodin DewaillyS. (1989). Long-term use of the low dose LHRH analogue combined with monthly medroxyprogesterone administration.Horm. Res.,32, 141–145\nAuthor information\nAuthors and Affiliations\nRights and permissions\nAbout this article\nCite this article\nLemay, A. Intranasal LHRH agonist combined periodically with a progestogen for contraception. Adv Contracept 5, 253–262 (1989). https://doi.org/10.1007/BF01890898\nIssue date:\nDOI: https://doi.org/10.1007/BF01890898","source_license":"public-domain-us","license_restricted":false}